Board of Directors
Robert Pelzer has served as a member of our Board of Directors since May 2015. From September 2008 to March 2013, Mr. Pelzer served as the President of Novartis Corporation, a pharmaceutical company. From 2002 to 2008, Mr. Pelzer served as General Counsel at Novartis Pharma AG. Prior to 2002, Mr. Pelzer held various positions, including serving as General Counsel and Senior Vice President at DuPont Pharmaceuticals from 1998 to 2001. Mr. Pelzer currently serves on the Board of Directors of Qu Biologics and previously served on the Board of Directors of Aquinox Pharmaceuticals and Idenix Pharmaceuticals, Inc. Mr. Pelzer holds a BComm and an LL.B. from the University of Alberta.
Gaurav Aggarwal, MD, has served as a Managing Director of Vivo Capital LLC, a healthcare focused investment firm, since October 2016, where he focuses on investments in life sciences companies. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, as Managing Director of Investor Growth Capital, and as a General Partner at Panorama Capital, L.P., a venture capital fund. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co. Dr. Aggarwal previously served on the Boards of Directors of Hyperion Therapeutics, Inc. (acquired by Horizon Pharma plc) and Microlin Bio, Inc. and on several privately held biopharmaceutical companies. Dr. Aggarwal received his MD from Columbia University, College of Physicians & Surgeons, and his BS in Agricultural Economics from Cornell University.
Dr. Allen is a co-founder of Gritstone Oncology and serves as its President, Chief Executive Officer and a member of its Board of Directors. He was a Co-Founder of Clovis Oncology (NASDAQ: CLVS) where he served as Executive Vice President of Clinical and Preclinical Development and Chief Medical Officer, leading the in-licensing and global development of RubracaTM, a PARP inhibitor approved for treatment of ovarian cancer. Prior to that, he was Chief Medical Officer at Pharmion Corporation, which was sold to Celgene Corporation for $2.9 billion following the global development of Vidaza™ for the treatment of myelodysplastic syndromes and Thalomid™ for the front-line treatment of multiple myeloma in Europe. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the Board of Directors of the epigenetic cancer therapy company, Epizyme (NASDAQ: EPZM), and Cell Design Labs, a privately held CAR-T company. Dr. Allen received a medical degree from Oxford University and a PhD in immunology from Imperial College London.
Mona Ashiya, PhD, is currently a Partner at OrbiMed Advisors, LLC, a healthcare focused investment firm. She has been at OrbiMed since 2010 where she has been involved with a number of investments in public and private biotech companies. Dr. Ashiya received her BA from the University of California, Berkeley and her PhD in Cellular, Molecular and Developmental Biology from the University of Pittsburgh.
Jeffrey Cooper has served as an independent consultant for life science companies since January 2014. Previously, Mr. Cooper served at KaloBios Pharmaceuticals, Inc., a biotechnology company, as a senior advisor from November 2013 until December 2013, and as the Chief Financial Officer from July 2012 until October 2013. Prior to joining KaloBios, Mr. Cooper served in positions of increasing responsibility at BioMarin Pharmaceutical, Inc., a pharmaceutical company, beginning as Vice President, Controller, to his most recent position as Senior Vice President and Chief Financial Officer from 2007 to May 2012. He has also served as Vice President of Finance at Matrix Pharmaceutical, Inc. and held numerous finance-related positions within the heath care and pharmaceutical industries, including Corporate Controller at Foundation Health Systems and Director of Business Analysis at Syntex Corporation. He previously served on the board of directors of Tobira Therapeutics, Inc. until it was acquired by Allergan plc in November 2016. Mr. Cooper received a BA from the University of California, Los Angeles and an MBA from Santa Clara University. He is a Certified Public Accountant, under inactive status, in the State of California.
Dr. Nick Glover is an accomplished life sciences professional, with extensive strategic, financial and operational experience in the biotechnology sector, evidenced by demonstrable value creation and successful outcomes. Previously, Dr. Glover served as the President and Chief Executive Officer at YM BioSciences Inc., a publically traded oncology drug development company acquired by Gilead Sciences Inc. in February 2013. YM’s lead drug candidate, momelotinib, was an orally administered JAK inhibitor being developed for the treatment of myelofibrosis and other hematological disorders. Prior to that, Dr. Glover served as the President and Chief Executive Officer of Viventia Bio Inc., a publically traded biopharmaceutical company focused on the development of monoclonal antibody technologies. Dr. Glover also previously served as an investment manager for MDS Capital, a life sciences venture capital firm. He currently serves on the board of directors of MEI Pharma Inc., a company developing novel therapies for hematology and oncology. Dr. Glover holds a BSc (Hons) in chemistry from the University of East Anglia, a MSc in chemistry from the University of British Columbia and a PhD in chemistry from Simon Fraser University.
Josh Richardson, MD, has served as Managing Director of Longitude Capital since February 2016 where he focuses on investments in biotechnology companies. From September 2014 to February 2016, Dr. Richardson served as a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments. Dr. Richardson received his BS in Biomedical Science from the University of South Florida, and his MD from the University of Virginia.
Andrew Sinclair, PhD, has served in various positions since November 2008 at Abingworth LLP, a life sciences investment group, where he currently serves as a Partner and Portfolio Manager. Dr. Sinclair currently serves on the Boards of Directors of Soleno Therapeutics, Inc. and Verona Pharma plc. Dr. Sinclair is a member of the Institute of Chartered Accountants in England and Wales. Dr. Sinclair received his BSc in Microbiology from King's College London and his PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich.